ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

Related Keywords

William Gradishar ,Rena Callahan ,Mabel Mardones ,Gregory Vidal ,Peer Exchange ,Oral Serd ,Mbc ,Metastatic Breast Cancer ,Iserd ,Therapeutic Advances ,Panel Discussion ,Her Positive ,Her2 Negative ,Selective Estrogen Receptor Degrader ,Endocrine Therapy ,Targeted Therapy ,Treatment Developments ,Medical Oncology ,Oncologist ,Breast Oncology ,Elacestrant ,Breast Cancer ,Clinical Guidelines ,Fda Label ,Nccn Guidelines ,Esr1 Mutations ,Treatment Resistance ,Moral Therapy ,Disease Progression ,Patient Profiles ,Precision Medicine ,Metastatic Cancer ,Treatment Sequencing ,Liquid Biopsy Tissue Testing ,Precision Oncology ,Therapeutic Strategies ,Treatment Failure Criteria ,Patient Selection ,Dosage Modifications ,Toxicity Comparison ,Breast Cancer Treatment ,